Aurora Cannabis Inc., in conjunction with its subsidiary MedReleaf Australia, announced the removal of the concession card requirement for patients to access medical cannabis products under the IndiMed brand. This change allows any patient in Australia to be prescribed IndiMed products, significantly broadening access.
IndiMed was initially launched in Australia in 2021 as the market's first concession product and has since expanded its portfolio to include oil, dried flower, and resin cartridges. IndiMed flower products consistently rank among the top 10 most prescribed flowers for cannabis patients.
This strategic adjustment reflects Aurora's dedication to supporting prescribers by simplifying prescribing options and adapting to meet patient demand in the rapidly growing Australian medical cannabis market. The move is expected to enhance market penetration for the popular brand.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.